TerminatedNCT06949657
Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and
This study assesses thinking abilities.
Interventional studyAges 60+China
Understand this study
What is this study about?
This study assesses thinking abilities.
Who could participate?
This study is for people with schizophrenia. Listed age limits: from 60 years. Other eligibility criteria apply.
- Listed locations
- HuzhouSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 13, 2023
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 78
- Sponsor
- Third People's Hospital, Huzhou City, Zhejiang Province, China
- Sponsor type
- Hospital / academic medical center
- Study type
- Other
- Intervention type
- Other
- Locations
- China
- Age range
- Over 60 Years
- Official registry ID
- NCT06949657
- Official title
Show the full official title
Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and the Application Effect of Acceptance and Commitment Therapy Nursing Model
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Huzhou
Interested in joining this study?
Questions about this study
What is this study about?
This study assesses thinking abilities.
Who is behind this study?
The study sponsor is Third People's Hospital, Huzhou City, Zhejiang Province, China, a hospital or academic medical center.
Who can participate?
This study is for people with schizophrenia. Listed age limits: from 60 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase